Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:
wherein:
R 1 is selected from the group consisting of hydrogen, halogen and a substituted or unsubstituted C 1 -C 6 alkyl;
Ring A is selected from the group consisting of a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-6 membered monocyclic heteroaryl;
Ring B is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl and a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl;
R 2 is selected from the group consisting of
m is 0, 1, 2 or 3;
R 3 is selected from the group consisting of halogen and a substituted or unsubstituted C 1 -C 6 alkyl;
X is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, a substituted or unsubstituted 4-6 membered monocyclic heterocyclyl, a substituted or unsubstituted amine(C 1 -C 6 alkyl), a substituted or unsubstituted —NH—(CH 2 ) 1-6 -amine, a mono-substituted amine, a di-substituted amine, an amino, a substituted or unsubstituted C 1 -C 6 alkyl, a substituted or unsubstituted C 1 -C 6 alkoxy, a substituted or unsubstituted C 3 -C 6 cycloalkoxy, a substituted or unsubstituted (C 1 -C 6 alkyl)acyl, a substituted or unsubstituted C-amido, a substituted or unsubstituted N-amido, a substituted or unsubstituted C-carboxy, a substituted or unsubstituted O-carboxy, a substituted or unsubstituted O-carbamyl and a substituted or unsubstituted N-carbamyl;
Y is CH or N;
Y 1 is CR 4A or N;
Y 2 is CR 4B or N;
Ring C is selected from the group consisting of a substituted or unsubstituted C 6 -C 10 aryl, a substituted or unsubstituted monocyclic 5-10 membered heteroaryl, a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl, a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl and a substituted or unsubstituted 7-10 membered bicyclic heterocyclyl;
R 4A and R 4B are independently selected from the group consisting of hydrogen, halogen and an unsubstituted C 1-4 alkyl; and
R 5 is a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl.
2. The compound of claim 1 , wherein R 1 is hydrogen.
3. The compound of claim 1 , wherein Ring A is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl.
4. The compound of claim 3 , wherein
is selected from the group consisting of:
wherein each of the aforementioned groups are substituted or unsubstituted.
5. The compound of claim 3 , wherein Ring A is unsubstituted.
6. The compound of claim 1 , wherein Ring B is a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl.
7. The compound of claim 6 , wherein Ring B is a substituted monocyclic 5 membered carbocyclyl.
8. The compound of claim 6 , wherein Ring B is substituted with 1, 2 or 3 substituents independently selected from the group consisting of fluoro, hydroxy, amino, an unsubstituted —NHC(O)C 1 -C 6 alkyl, an unsubstituted C 1 -C 6 haloalkyl and an unsubstituted C 1 -C 6 alkyl.
9. The compound of claim 1 , wherein R 2 is
wherein Y is CH.
10. The compound of claim 9 , wherein X is a substituted or unsubstituted 4-6 membered monocyclic heterocyclyl.
11. The compound of claim 10 , wherein X is selected from the group consisting of a substituted or unsubstituted azetidine, a substituted or unsubstituted oxetane, a substituted or unsubstituted diazetidine, a substituted or unsubstituted azaoxetane, a substituted or unsubstituted pyrrolidine, a substituted or unsubstituted tetrahydrofuran, a substituted or unsubstituted imidazoline, a substituted or unsubstituted pyrazolidine, a substituted or unsubstituted piperidine, a substituted or unsubstituted tetrahydropyran, a substituted or unsubstituted piperazine, a substituted or unsubstituted morpholine and a substituted or unsubstituted dioxane.
12. The compound of claim 10 , wherein X is substituted.
13. The compound of claim 12 , wherein X is substituted with 1 or 2 substituents independently selected from the group consisting of fluorine, an unsubstituted C 1 -C 6 alkyl, an unsubstituted C 1 -C 6 hydroxyalkyl, an unsubstituted amine(C 1 -C 6 alkyl) and an unsubstituted (C 1 -C 6 alkyl)acyl.
14. The compound of claim 1 , wherein R 2 is
15. The compound of claim 9 , wherein m is 0.
16. The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
17. The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
18. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
19. A method for ameliorating or treating a cancer comprising administering an effective amount of claim 1 , or a pharmaceutically acceptable salt thereof, to a subject having the cancer, wherein the cancer is selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma.
20. A method for inhibiting replication of a malignant growth or a tumor comprising contacting the malignant growth or the tumor with an effective amount of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the malignant growth or tumor is due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma.
21. A method for ameliorating or treating a malignant growth or a tumor comprising contacting the malignant growth or the tumor with an effective amount of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the malignant growth or tumor is due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma.
22. The compound of claim 16 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
23. The compound of claim 16 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
24. The compound of claim 16 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
25. The compound of claim 16 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
26. The compound of claim 17 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
27. The compound of claim 17 , wherein the compound is
or a pharmaceutically acceptable salt thereof.